DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase
February 29, 2024 05:42 ET
|
Mithra Pharmaceuticals
DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase Mithra on-track for completion of Phase 3 study for DONESTA® to treat...
Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel
December 21, 2023 11:45 ET
|
Mithra Pharmaceuticals
Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel Rafa Laboratories to receive the exclusive commercial rights for DONESTA® in Israel on the...
Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China
December 04, 2023 01:00 ET
|
Mithra Pharmaceuticals
Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China Mithra signs binding Head of Terms for a twenty-year partnership with Gedeon-Richter...
Mithra Announces Information on the Total Number of Voting Rights (Denominator)
June 26, 2023 11:45 ET
|
Mithra Pharmaceuticals
Mithra Announces Information on the Total Number of Voting Rights (Denominator) Liege, Belgium, 26 June 2023 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s...
Mithra - Letter to Shareholders and Corporate Update
May 25, 2023 01:30 ET
|
Mithra Pharmaceuticals
Letter to Shareholders and Corporate Update Access to EUR15 million under amended dealDonesta® U.S. marketing deal is a key near term priorityCDMO strategic options are being exploredDonesta®...
Mithra - Letter to Shareholders and Corporate Update
May 25, 2023 01:30 ET
|
Mithra Pharmaceuticals
Letter to Shareholders and Corporate Update Access to EUR15 million under amended dealDonesta® U.S. marketing deal is a key near term priorityCDMO strategic options are being exploredDonesta®...